Breast Cancer Characteristics and Survival in a Hispanic Population of Costa Rica

Nadia Sru-r-Rivero¹ and Mayra Cartin-Brenes²

¹Servicio de Oncología Quirúrgica, Unidad de Mama, Hospital San Juan de Dios, Caja Costarricense de Seguro Social, San Jose, Costa Rica. ²Escuela de Salud Pública, Universidad de Costa Rica, San Pedro Montes de Oca, Costa Rica.

ABSTRACT

BACKGROUND: Breast cancer characteristics may vary according to the patient’s ethnic group. The goal of this cohort study was to evaluate the characteristics of a group of Costa Rican breast cancer patients and their relationship with survival.

METHODS: Age, stage, tumor grade, immunohistochemistry, lymphovascular invasion, recurrence, and survival data on 199 Hispanic patients with breast cancer diagnosis, treated between January 2009 and May 2010, were collected from a single institution in San Jose, Costa Rica. The data were statistically analyzed for significance.

RESULTS: Median age at diagnosis was 53 years. With a median follow-up of 46.5 months, there was an 88% overall survival rate. Thirty-seven percent of the patients (p < 0.001) were at stages III and IV during diagnosis. The hormone receptor human epidermal receptor negative phenotype (HR–HER2–) (p < 0.001) was present in 17% of the cases. In a multivariate analysis, local (risk ratio, RR: 7.2; confidence interval, CI 95%: 3.8–7.6; p = 0.06) and distant recurrence (RR: 14.9; CI 95%: 7.7–28.9; p = 0.01) showed the strongest association with the probability of death from the disease. Patients with HR–HER2– phenotype tumors reported more local recurrences (p = 0.04), a higher tumor grade (p < 0.01), and lower overall survival than patients with other breast cancer phenotypes (p = 0.01).

CONCLUSIONS: Although this study analyzes a modest number of cases, it is an initial insight into factors that may contribute to differences in breast cancer outcomes among Hispanic women in Costa Rica. The higher proportion of triple negative tumors, advanced stage, and younger median age at diagnosis could contribute to the inferior prognosis described among Hispanic women. There may be a different distribution of tumor subtypes compared to non-Hispanic white women. Further studies are necessary to confirm such findings.

KEYWORDS: breast, cancer, Hispanic, Costa Rica, immunohistochemistry

Introduction

The population in Costa Rica recently diagnosed with breast cancer is increasing. According to statistics from Costa Rica’s National Cancer Registry, the adjusted incidence rate has increased from 37.66 to 44.09 per 100,000 women in 10 years, and breast cancer is the leading cause of cancer-related death in women.¹ Characteristics of the disease appear to be different according to the patient’s ethnic group. Hispanic women seem to have an increased mortality risk after being diagnosed with breast cancer, are diagnosed at a later stage,²–⁴ report a lower median age at diagnosis,⁵–⁷ and feature a different immunohistochemical tumor subtype distribution, compared to non-Hispanic white women.⁶–⁸
Hormone receptors (HR) are proteins expressed in breast epithelium and stroma that bind to circulating hormones to trigger cellular changes. The HRs more extensively studied in breast cancer are estrogen receptors (ER) and progesterone receptors (PR). Patients diagnosed with HR+ tumors are usually older, more responsive to hormone therapy, and tend to have better disease-free and overall survival.

HER2 is a transmembrane tyrosine kinase receptor that belongs to the epidermal growth factor group, encoded by the ERBB2-HER2 oncogene. Its overexpression is associated with a more aggressive cancer behavior and worse prognosis. Therapy with the humanized monoclonal antibody Trastuzumab directed to the HER2 receptor has shown an inhibitory effect on tumor growth.

Tumors lacking HR and HER2 expression are associated with younger age at diagnosis, a more aggressive clinical course and worse results than other breast cancer subtypes. The HR–HER2– subtype has been found in higher proportion in African-American and Hispanic, than in Caucasian and Asian breast cancer patients.

This cohort study aims to evaluate the traits of a Hispanic group of breast cancer patients, such as mean age at diagnosis, stage of disease, tumor grade, immunohistochemistry (IHC), and their relationship with survival. The purpose is to contribute to improve health programs and adapt them to the patient’s requirements.

Methodology
We requested the statistics department at San Juan de Dios Hospital of the Costa Rican Social Security System (Caja Costarricense del Seguro Social), a reference cancer treatment center for Costa Rica’s South Central Region, to provide a list of patients with “breast cancer” diagnosis discharged from the Hospital from January 2009 to May 2010. The study procedures were approved by the hospital’s institutional review board.

The analysis included all Hispanic women newly diagnosed with in situ or invasive breast cancer. A group of 199 patients was continuously selected from the list by the medical records department and clinical-pathological data were collected for each patient. The data analyzed in each medical record, if any, were patient’s age in years, ethnicity, cancer stage, subsequent hospitalizations, operative note, pathology report, and follow-up visits to the Hospital until June 1, 2013.

Information on stage and lymph node status was collected according to the American Joint Committee on Cancer’s (AJCC, 7th edition) staging criteria. The histopathological type was classified as ductal, lobular, both, or other. Histologic grading was classified according to the modified Bloom and Richardson method by Elston and Ellis (Nottingham’s grading system). Lymph vessel invasion was assessed using hematoxylin–eosin stained glass slides. Vascular channels lined by thin endothelial cells, especially close to the small arteries and veins, were considered as lymph vessels, and tumor emboli were floating in the lumen in lymph vessel invasion-positive cases.

Immunohistochemical subtypes such as ER, PR, and HER2 status were determined by IHC. Antigen retrieval was performed in a decloaking steam chamber. Manual antibody incubation, DAKO “in vision” detection system, DAB Chromogen System, and bluish Gill H&E staining using lithium carbonate were used. For HR receptor staining, primary antibodies were applied at a 1:30 dilution for 1 hour. After 30-minute incubation with a secondary antibody, DAKO detection solution was applied. The last step was the addition of a substrate–chromogen solution. The cutoff for receptor positivity was 1%.

For HER2 staining, primary HER2 antibodies were applied for 30 minutes. After 30-minute incubation with a secondary antibody, a substrate–chromogen solution was added. It was scored on a qualitative scale based on staining intensity: 0 and 1+ were negative; 2+ was considered positive; and 2+ was considered borderline, and sent to an external laboratory for fluorescence in situ hybridization (FISH) evaluation. FISH was scored on a quantitative scale: less than 2 copies of the HER2 gene was negative, and 2 or more copies was HER2-positive.

Follow-up visits until June 1, 2013 were analyzed for distal or local recurrence. Patients with initial metastatic disease were separated from patients who experienced distant recurrence a period of time after initial diagnosis. The survival status and date of death were confirmed at the Civil Registry of Costa Rica on a case-by-case basis. Survival time was defined in days from the time of diagnosis at the hospital to the date of death, or survival confirmation on June 1, 2013. Seven variables were selected and identified by their significance for mortality statistical analysis.

Statistical Analysis
Sample size. In 2009 and 2010, there were a total of 957 and 997 newly diagnosed breast cancer cases in Costa Rica. The sample size was calculated based on 87% expected survival, which in statistical terms is a proportion, for which the formula \( N = Z^2 \times P \times (1 – P)/D^2 \) was used, where \( Z = CI \) chosen (if \( \alpha = 95\%, Z = 1.96 \)); \( P = \) expected ratio, 0.87; \( D = \) maximum error, 0.05; and \( n = \) sample size, 173. Although the recommended sample size is 173 cases, information for more cases was collected due to the probability of finding records with incomplete information. Since the information was obtained retrospectively from medical records, selection bias was avoided because the sample was selected randomly.

For descriptive purposes, continuous variables were summarized as arithmetic means with standard deviations and medians with ranges, and categorical variables were summarized as relative frequencies, ratios, and 95% CIs. Inferential comparisons were performed using the Student’s \( t \)-test or the
Mann–Whitney U test according to distribution (normal or not normal) determined by the Kolmogorov–Smirnov test. Pearson chi-square tests and relative risk ratios (RRs) were used to compare the clinical and pathological variables. For the multivariate analysis, the variables included were those bearing clinical significance and those that were significant or nearly statistically significant ($p < 0.05$) in the univariate analysis.

All variables were dichotomized for survival analysis. Adjustment of potential confounders was carried out with Cox proportional hazards regression analysis. All tests were two-sided, and significance was set at $p > 0.05$. SPSS software (version 20.0; SPSS, Chicago, IL) was used for data analysis purposes.

Differences between breast cancer subtypes with regards to clinical-pathological characteristics were examined using analysis of variance, $\chi^2$ tests, or Fisher’s exact test. The log-rank test was used to compare mean survival across IHC subtypes. StatView statistical software (version 3.0; Abacus, Baltimore, MD) was used to manage and analyze data. Statistical differences were considered significant at $p \leq 0.05$.

**Results**

Clinical-pathological and non-cancer specific survival data on 199 Hispanic patients with breast cancer diagnosis were collected from a single institution in San Jose, Costa Rica.

Table 1 displays the population’s general characteristics. Median age at breast cancer diagnosis was 53 years. The histopathological type was 80% ductal carcinoma. Stage was distributed as follows: Stage 0, 3%; stages I and II, 59.3%; and stages III and IV, 37.1%. Survival for a median follow-up of 46.5 months was 88%. The immunohistochemical subtypes were HR+/HER2–, 62.3%; HR+/HER2+, 9%; HR–HER2+, 9.5%; and HR–HER2–, 17.1%. The proportion of HR– and/or HER2+ tumors was higher for patients under 50 years old, when compared to their white counterparts (47%).

Differences in histological grade were statistically significant ($p < 0.01$): HR–HER2–, 91.9%; HR–HER2+, 94.4%; HR–HER2+, 89.5%; and HR–HER2–, 73.5%.

Patients with HR+ and HER2+ overexpression tumors are more likely to present with an advanced stage than patients with HR–HER2– tumors; however, this was not statistically significant ($p = 0.18$). No significant differences were found in age ($p = 0.44$), lymphovascular invasion ($p = 0.86$), and distant recurrence ($p = 0.42$) between subgroups.

**Discussion**

The median age at diagnosis of this group of patients was 53 years. Different to the mean age at breast cancer diagnosis of 61–63 years among Australian and European women; a younger median age at cancer diagnosis has been described for Hispanic women. In some studies, the median age is 10 years younger than the average age reported in the United States, and there is a higher proportion of non-Hispanic whites (57%) diagnosed with breast cancer younger than 60-years old, when compared to their white counterparts (47%).

The distribution of breast cancer subtypes among young patients has been found to be different from that observed in older women, and has further variations with race/ethnicity. Young women are also more likely to be diagnosed with stages III/IV disease and high-grade tumors than older women. Hispanics are described as the ethnic group with the highest percentage of women under 41 years diagnosed with breast cancer.

Thirty-seven percent of the patients in the group had stages III and IV cancer at diagnosis. This is much higher than the number described in other studies for Central and South American women with stages III and IV cancer at diagnosis (14.3%). Social and cultural barriers, like “fear to be left by her partner, poor awareness of the population and primary health providers, as well as deficient mammographic screening programs,” could lead to an advanced stage at diagnosis. Hispanic women have been found to have a 1.7- to 2.5-fold elevation in the risk of stages III and IV tumors, compared to non-Hispanic whites. Warner et al found Hispanic and other minority women were more likely to show up with cancer symptoms versus a problem detected through screening mammography, and experienced longer times from initial signs of cancer to final diagnosis.
Table 1. General characteristics of patients with breast cancer in Costa Rica.

| NO. OF PATIENTS, (%) | P VALUE* |
|----------------------|---------|
| **Age, years-old**   |         |
| <50 years            | 74 (37.2)|         |
| 50–70 years          | 103 (51.8)| .03     |
| >70 years            | 22 (11.1)|         |
| **AJCC stage**       |         |
| 0                    | 6 (3)   |         |
| I                    | 35 (17.6)|         |
| IA                   | 31 (15.6)|         |
| IB                   | 4 (2)   |         |
| II                   | 83 (41.7)|         |
| IIA                  | 50 (25.1)|         |
| IIB                  | 33 (16.6)| <.001   |
| III                  | 67 (33.6)|         |
| IIIA                 | 38 (19.1)|         |
| IIIB                 | 15 (7.5) |         |
| IIIC                 | 14 (7)  |         |
| IV                   | 7 (3.5)  |         |
| Missing              | 1 (0.5)  |         |
| **Immunohistochemical (IHC) subtype** |         |
| HR+ HER2–             | 124 (62.3)|         |
| <50 years            | 41 (20.6)|         |
| >50 years            | 83 (41.7)|         |
| HR+ HER2+            | 18 (9)  |         |
| <50 years            | 8 (4.02) |         |
| >50 years            | 10 (5.02)|         |
| HR– HER2–            | 19 (9.5) | .02     |
| <50 years            | 10 (5.02)|         |
| >50 years            | 9 (4.52) |         |
| HR– HER2+            | 34 (17.1)|         |
| <50 years            | 14 (7.03)|         |
| >50 years            | 20 (10.05)|        |
| Missing              | 4 (2.01) |         |
| **Histologic grade** |         |
| Grade I              | 27 (13.6)|         |
| Grade II             | 74 (37.2)| .33     |
| Grade III            | 62 (31.1)|         |
| Missing              | 36 (18.1)|         |
| **Lymphovascular**   |         |
| Invasion present     | 34 (17.08)|        |
| Absent               | 66 (33.16)| .015   |
| Missing              | 99 (49.74)|        |
| **Local recurrence** |         |
| Present              | 7 (3.58) | <.001   |
| Absent               | 192 (98.46)|        |
| **Distal**           |         |
| Recurrence           | 11 (5.53)|         |
| Present              | 182 (91.46)| <.001 |
| Absent               | 6 (3.02) |         |
| **Stage IV**         |         |

Notes: *Univariate analysis. **IHC subtype and age.

The group of patients diagnosed with stage I disease was small (17.6%). In previous publications, only a small percentage of Hispanic women are diagnosed with stage I breast cancer.6–14 Walters et al reported that stage I at diagnosis ranged from 30% to 45%, and stages III and IV from 8% to 22%, depending on the screening program implemented by the country, in a European, Canadian, and Australian population study.11 Sassi et al described that Hispanic women who developed breast cancer had somewhat lower probability of early stage diagnosis than non-Hispanic white women, but with more steeply increasing screening rates, there was a similar increase in the number of cases diagnosed at an early stage.15 Rodriguez-Cuevas et al described results of a first mammography screening program in Mexico. Even though it was a case study of 208 patients, one-third of diagnosis were stage 0 or I, 42%, stage II and 26.7%, stage III. These results were different from other published data of Mexican breast cancer series, in which 25–40% were stages I and II and 57% were stages III and IV.5

In our study, the percentage for the HR+ HER2– phenotype is higher (17.1%) than in non-Hispanic whites (11.7–12.5%).6,8 This proportion (17.2–17.3%) has been reported for Hispanics in previous studies,6,10 which is higher than the one reported for Japanese patients (8%),17 but lower than for African-Americans (24.6–27.9%).8,10 A higher proportion of HR+ HER2– (23%) has also been described by Lara-Medina et al in Hispanic patients.6

Patients with HR+ HER2– phenotype tumors experienced more local recurrences, had higher tumor grades, and lower overall survival than patients with other breast cancer phenotypes. Hispanics have been found more likely to present high-grade tumors than non-Hispanic whites.7 HR+ HER2– tumors exhibit in average a high-grade tumor: over 80% of HR+ HER2– tumors have high histologic grade, compared to less than 20% of the HR+ HER2– tumors.8,18 Local recurrence has been described as three times higher in patients with the HR+ HER2– phenotype than with the HR+ HER2– phenotype.18

Three-year survival for HR+ HER2– patients was lower than for patients with other immunohistochemical subtypes (73.5%). In California studies, survival among women with HR+ HER2– breast cancer was lower: they reported a 76–77% 5-year survival rate, compared to 93–96% 5-year survival rate for women with other types of breast cancer.16,19 In Japanese women, there was also a lower overall survival (86.2%) for basal-like cancer than for the luminal A phenotype (96.9%).17

With a median follow-up of 46.5 months, there was an 88% survival rate for patients in this group. There was a 3-year overall survival rate of 91% to 94% in other two European countries, Canada, and Australia, compared to 87% and 89% in UK and Denmark, related to screening implementation and differences in treatment.11 Hispanics have been described to have a 1.3– to 2-fold increase in mortality risk compared to non-Hispanic whites.2,21
Table 2. Dichotomized clinico-pathologic characteristics of patients with breast cancer in Costa Rica.

| CHARACTERISTIC            | NO. OF PATIENTS, (%) | UNIVARIATE ANALYSIS | MULTIVARIATE LOGISTIC REGRESSION ANALYSIS |
|---------------------------|----------------------|---------------------|------------------------------------------|
|                           | ALIVE | DEAD | P | RR (95% CI) | P | RR (95% CI) |
| Age                       |       |      |   |            |   |            |
| <50 years                 | 71    | 3    | 95.9% | 4.1% | .01 | 4.1 (1.2–13.4) | .95 |
| >50 years                 | 104   | 17   | 86.0% | 14.0% | <.01 | .58 (2.25–414.9) | .59 |
| AJCC stage                |       |      |   |            |   |            |
| I and II                  | 113   | 5    | 95.8% | 4.2% | .95 | NA |
| III and IV                | 55    | 18   | 75.3% | 24.7% | <.001 | 1.8 (0.74–4.5) | NA |
| Histologic grade          |       |      |   |            |   |            |
| 1 and 2                   | 93    | 8    | 92.1% | 7.9% | .18 | 1.8 (0.74–4.5) | NA |
| 3                         | 53    | 9    | 85.5% | 14.5% | .94 | NA |
| Lymphovascular invasion   |       |      |   |            |   |            |
| Absent                    | 34    | 0    | 100% | 0% | .015 | NA |
| Present                   | 52    | 14   | 76.8% | 23.2% | NA | .94 |
| Distant recurrence        |       |      |   |            |   |            |
| No                        | 172   | 10   | 94.5% | 5.5% | .001 | 14.9 (7.7–28.9) | .01 |
| Yes                       | 2     | 9    | 18.2% | 81.8% | .06 | NA |
| Local recurrence          |       |      |   |            |   |            |
| No                        | 173   | 19   | 90.1% | 9.9% | .001 | 7.2 (3.8–13.6) | .06 |
| Yes                       | 2     | 5    | 28.6% | 71.4% | .001 | 7.2 (3.8–13.6) | .06 |
| Immunohistochemical subtype|       |      |   |            |   |            |
| HR+HER2−, HR+HER2+, and HR−HER2+ | 148 | 13   | 91.9% | 8.1% | .001 | 2.7 (1.2–5.8) | .93 |
| HR−HER2−                  | 25    | 9    | 73.5% | 26.5% | .001 | 2.7 (1.2–5.8) | .93 |

Abbreviations: RR, relative risk; CI, confidence interval.

Table 3. Prevalence of immunohistochemical subtypes and clinico-pathologic characteristics of patients in Costa Rica.

| ALL CASES | HR+HER2− | HR+HER2+ | HR−HER2+ | HR−HER2− | P VALUE* |
|-----------|----------|----------|----------|----------|----------|
| Number of cases | 195 | 124 | 18 | 19 | 34 |
| Age, median (range), years-old | 53 (24–88) | 54 (24–86) | 50.5 (29–71) | 49 (26–72) | 52 (27–88) |
| AJCC stage |       |      |   |            |   |            |
| I and II | 114 | 81 | 8 | 7 | 18 |
| III and IV | 74 | 42 | 7 | 10 | 15 |
| 0 | 6 | 1 | 0.5% |   |   |
| Missing | 1 | 0 | 1 | 0.5% |   |   |
| Histologic grade |       |      |   |            |   |            |
| I and II | 99 | 79 | 9 | 50.0% | 8 | 42.1% | 3 |
| III | 61 | 27 | 5 | 27.8% | 7 | 36.8% | 22 |
| Missing | 35 | 18 | 4 | 22.2% | 4 | 21.1% | 9 |
| Lymphovascular invasion |       |      |   |            |   |            |
| Present | 34 | 24 | 3 | 16.7% | 2 | 10.5% | 5 |
| Absent | 66 | 43 | 5 | 27.8% | 7 | 36.8% | 11 |
| Missing | 95 | 57 | 10 | 55.6% | 10 | 52.6% | 18 |
| Local recurrence |       |      |   |            |   |            |
| Present | 7 | 3 | 0 | 2.4% | 0 | 0% | 4 |
| Absent | 188 | 121 | 18 | 100.0% | 19 | 100.0% | 30 |
| Distant recurrence |       |      |   |            |   |            |
| Present | 11 | 6 | 0 | 4.9% | 0 | 0% | 2 |
| Absent | 178 | 116 | 17 | 100% | 17 | 89.5% | 28 |
| Initial stage IV |       |      |   |            |   |            |
| Follow-up, median (range), months | 45.6 (2–55.4) | 45.6 (2–55.4) | 45.6 (2–55.4) | 45.6 (2–55.4) | 45.6 (2–55.4) |
| Overall survival | 88.7% | 91.9% | 94.4% | 89.5% | 73.5% | .01** |

Notes: *Compares four subtypes using Fisher’s exact text. **Log rank test.
Hines et al found tumor single marker staining for HER2+ was 31.9% in Hispanics, compared to 14.3% in non-Hispanic whites. In our study, 18.5% of the tumors displayed single marker staining for HER2+, or were FISH+. The slightly higher survival in this study for the HR+HER2+ subtype compared to the HR+HER2− may be explained in part by public access to treatment and systemic therapies, as well as sample size and short follow-up period.

Information from patient records was not found for tumor grade in 18.1% of the cases and for lymphatic invasion in 50% of the cases. No standardized synoptic report for breast cancer was used by pathologists at the time; therefore, information was omitted in some pathology reports. Future changes in reporting are expected with the recent implementation of the standardized synoptic report for breast pathology, and the assignment of a specialized group of pathologists to work on breast diseases.

The study’s weakness is that the patient cohort is from a single institution, which is a reference cancer treatment center for Costa Rica’s South Central Region; hence, the data may not reflect the true epidemiology of the entire Hispanic population in Costa Rica.

This is the first published study of breast cancer clinical-pathological characteristics and survival of Costa Rican breast cancer patients, according to Medline search terms: breast cancer, Costa Rica.

Conclusions
These findings may provide an initial insight to factors that contribute to differences in breast cancer outcomes among Hispanic women in Costa Rica. The higher proportion of triple negative tumors, advanced stage, and younger median age at diagnosis could lead to a worse cancer prognosis in this group.

The higher proportion of stages III and IV tumors at diagnosis demands a review of the region’s breast cancer screening program. It is important to make emphasis on breast cancer awareness programs for the population and primary care physicians, and to investigate social and cultural barriers that make earlier cancer detection a difficult task.

Since patients are diagnosed at a younger age, it is desirable to organize programs for fertility preservation and genetic testing, among others, to improve patient care.

Acknowledgments
We thank Allan Ramos MD for providing data collection support, and Yetty Vargas MD, Adonay Jaen and Jason, San Juan de Dios IHC pathology technicians for their help with the IHC specifications for our study. We also thank Angela Ulloa for her help editing the manuscript.

Author Contributions
Conceived and designed the experiments: NSR. Analyzed the data: NSR, MCB. Wrote the first draft of the manuscript: NSR. Contributed to the writing of the manuscript: NSR, MCB. Agree with manuscript results and conclusions: NSR, MCB. Jointly developed the structure and arguments for the paper: NSR, MCB. Made critical revisions and approved final version: NSR, MCB. All authors reviewed and approved of the final manuscript.

REFERENCES
1. Ministerio de Salud, Memoria Institucional. Capítulo IV. análisis y determinantes sociales de la situación de salud. 2011:27–59. Disponible en. Available at http://www.ministerioedesalud.go.cr/cri/crec ministrioio/memorias/memoria2012/UMI_analisis_determinantes_sociales2011.pdf
2. Li CI, Malone KE, Darling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med. 2003;163:49–56.
3. Warner ET, Tamimi RM, Hughes ME. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat. 2012;136:813–821.
4. Chavarrí-Guerra Y, Villarreal-Garza C, Liedke PE, et al. Breast cancer in Mexico: a growing challenge to health and the health system. Lancet Oncol. 2012;13(8):e335–e344.
5. Rodríguez-Cuevas S, Guisa-Hohenstein F, Labastida-Almendaro S. First breast cancer mammography screening program in Mexico: initial results 2005–2006. The Breast. 2009;15:63–631.
6. Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117(10):3658–3669.
7. Hines LM, Risendal B, Byers T, Mengshol S, Lowery J. Ethnic disparities in breast tumor phenotype subtypes in Hispanic and non-Hispanic white women. J Women’s Health (Larchmt). 2011;20(10):1543–1550.
8. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Curr Res Oncol Hematol. 2010;26:44–52.
9. Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA. Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers. 2014;31:1581–31.
10. Parise CA, Bauer KR, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. A population-based study from the California cancer registry. Cancer. 2007;109(9):1721–1728.
11. Winter S, Maringe C, Butler J, et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000–2007: a population-based study. Br J Cancer. 2013;108:1195–1208.
12. García-Jiménez L, Gutiérrez-Espeleta G, Nordal SA. Descriptive epidemiology and molecular genetics of hereditary breast cancer in Costa Rica. Rev Biol Trop. 2012;60(4):1663–1669.
13. Keegan TH, DeRozen MC, Press DJ, Kuriaw AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res. 2012;14:R55.
14. Kouri EM, He Y, Winer EP, Keating NL. Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women. Breast Cancer Res Treat. 2010;121:741–751.
15. Sassi F, Luft HS, Guadagnoli E. Reducing racial/ethnic disparities in female breast cancer: screening rates and stage at diagnosis. Am J Public Health. 2006;96(12):2165–2172.
16. Ortiz AP, Frias O, Pérez J, et al. Breast cancer molecular markers and survival in a hospital-based sample in Puerto Rico. Cancer Med. 2013;2(3):343–350.
17. Kurebayashi J, Moriya T, Ishida T, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast. 2007;16:572–577.
18. Choo J, Kim DH, Jung WH, Koo JS. Differential expression of immune-related markers in breast cancer by molecular phenotypes. Breast Cancer Res Treat. 2013;137:471–482.
19. Parise CA, Bauer KR, Brown M. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J. 2009;15(6):593–602.
20. Brown M, Tsvodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer. The California cancer registry, 1999–2004. Cancer. 2008;112(4):737–747.
21. Ortiz-Barboza A, Gomez L, Cubero C, Bonilla G, Mena H. Cancer survival in Costa Rica, 1995–2000. JARC Srl Publ. 2011;162:85–88.